Caspase-3 (Cleaved)

Concentrated and Prediluted Polyclonal Antibody 901-229-091217



Catalog Number: CP 229 A, B, C **PP 229 AA**

Description: 0.1, 0.5, 1.0 ml, concentrated 6.0 ml, prediluted

Dilution: 1:100 Ready-to-use

Diluent: Da Vinci Green N/A

Intended Use:

For In Vitro Diagnostic Use

Caspase-3 (Cleaved) is a rabbit polyclonal antibody that is intended for laboratory use in the qualitative identification of caspase-3 protein by immunohistochemistry (IHC) in formalin-fixed paraffin-embedded (FFPE) human tissues. The clinical interpretation of any staining or its absence should be complemented by morphological studies using proper controls and should be evaluated within the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.

Summary and Explanation:

Apoptosis has gained central importance in the study of many biological processes, including neoplasia, neurodegenerative diseases, and development. Caspases (cysteinyl-aspartic acid proteases) play a key role in the execution of apoptosis. Activation of caspase-3 requires proteolytic processing of its inactive zymogen into active p17 and p12 subunits. Caspase-3 (Cleaved) detects the large fragment (17/19 kDa) of activated caspase-3 resulting from cleavage adjacent to (Asp175). This antibody does not cross-react with other cleaved caspases.

Principle of Procedure:

Antigen detection in tissues and cells is a multi-step immunohistochemical process. The initial step binds the primary antibody to its specific epitope. After labeling the antigen with a primary antibody, an enzyme labeled polymer is added to bind to the primary antibody. The detection of the bound antibody is evidenced by a colorimetric reaction.

Source: Rabbit polyclonal

Species Reactivity: Human and mouse

Clone: N/A Isotype: N/A

Total Protein Concentration: ~10 mg/ml. Call for lot specific Ig

Epitope/Antigen: Caspase-3

Cellular Localization: Cytoplasmic / nuclear Positive Tissue Control: Tonsil or colon cancer

Known Applications:

Immunohistochemistry (formalin-fixed paraffin-embedded tissues)

Supplied As: Buffer with protein carrier and preservative

Storage and Stability:

Store at 2°C to 8°C. Do not use after expiration date printed on vial. If reagents are stored under conditions other than those specified in the package insert, they must be verified by the user. Diluted reagents should be used promptly; any remaining reagent should be stored at 2°C to 8°C.

Protocol Recommendations:

Peroxide Block: Block for 5 minutes with Biocare's Peroxidazed 1. Pretreatment: Perform heat retrieval using Biocare's Reveal Decloaker. Refer to the Reveal Decloaker product data sheet for specific instructions.

Protein Block (Optional): Incubate for 5-10 minutes at RT with Biocare's Background Punisher.

Primary Antibody: Incubate for 30 minutes at RT

Probe: N/A

Polymer: Incubate for 30 minutes at RT with a secondary-conjugated polymer.

Protocol Recommendations:

Chromogen: Incubate for 5 minutes at RT with Biocare's DAB - OR -Incubate for 5-7 minutes at RT with Biocare's Warp Red.

Counterstain:

Counterstain with hematoxylin. Rinse with deionized water. Apply Tacha's Bluing Solution for 1 minute. Rinse with deionized water.

Technical Note:

This antibody has been standardized with Biocare's MACH 4 detection system. Use TBS buffer for washing steps.

Limitations:

The optimum antibody dilution and protocols for a specific application can vary. These include, but are not limited to: fixation, heat-retrieval method, incubation times, tissue section thickness and detection kit used. Due to the superior sensitivity of these unique reagents, the recommended incubation times and titers listed are not applicable to other detection systems, as results may vary. The data sheet recommendations and protocols are based on exclusive use of Biocare products. Ultimately, it is the responsibility of the investigator to determine optimal conditions. The clinical interpretation of any positive or negative staining should be evaluated within the context of clinical presentation, morphology and other histopathological criteria by a qualified pathologist. The clinical interpretation of any positive or negative staining should be complemented by morphological studies using proper positive and negative internal and external controls as well as other diagnostic tests.

Quality Control:

Refer to CLSI Quality Standards for Design and Implementation of Immunohistochemistry Assays; Approved Guideline-Second edition (I/LA28-A2). CLSI Wayne, PA, USA (www.clsi.org). 2011

Precautions:

- 1. This antibody contains less than 0.1% sodium azide. Concentrations less than 0.1% are not reportable hazardous materials according to U.S. 29 CFR 1910.1200, OSHA Hazard communication and EC Directive 91/155/EC. Sodium azide (NaN3) used as a preservative is toxic if ingested. Sodium azide may react with lead and copper plumbing to form highly explosive metal azides. Upon disposal, flush with large volumes of water to prevent azide build-up in plumbing. (Center for Disease Control, 1976, National Institute of Occupational Safety and Health, 1976) (2)
- 2. Specimens, before and after fixation, and all materials exposed to them should be handled as if capable of transmitting infection anddisposed of with proper precautions. Never pipette reagents by mouth and avoid contacting the skin and mucous membranes with reagents and specimens. If reagents or specimens come in contact with sensitive areas, wash with copious amounts of water. (3)
- 3. Microbial contamination of reagents may result in an increase in nonspecific staining.
- 4. Incubation times or temperatures other than those specified may give erroneous results. The user must validate any such change.
- 5. Do not use reagent after the expiration date printed on the vial.
- 6. The SDS is available upon request and is located at http://biocare.net.

Troubleshooting:

Follow the antibody specific protocol recommendations according to data sheet provided. If atypical results occur, contact Biocare's Technical Support at 1-800-542-2002.



Pacheco, CA 94553 USA





Caspase-3 (Cleaved)

Concentrated and Prediluted Polyclonal Antibody 901-229-091217



References:

- 1. Gown AM, Willingham MC. Improved detection of apoptic cells in archival paraffin sections: Immunohistochemistry using antibodies to cleaved capsase 3. J Histochem Cytochem. 2002 Apr;50(4):449-54.
- 2. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 "Decontamination of Laboratory Sink Drains to Remove Azide Salts."
- 3. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline-Fourth Edition CLSI document M29-A4 Wayne, PA 2014.

USA